Corcept Presents Complete Data From Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus...
Corcept Therapeutics presented final overall survival results from the phase 3 ROSELLA trial, showing that Lifyorli™ (relacorilant) combined with nab‑paclitaxel cuts the risk of death by 35 percent and adds 4.1 months to median survival versus chemotherapy alone. The regimen met both overall and progression‑free survival endpoints without added safety concerns and received FDA approval in March 2026. It has been incorporated as a preferred option in the NCCN Guidelines for platinum‑resistant ovarian cancer. The data were disclosed at the SGO 2026 meeting and published in The Lancet.
Dynamic Enzyme Complex Maps Nicotine Biosynthesis in Wild Tobacco
The complete biosynthetic pathway of nicotine in wild tobacco has been mapped, revealing a dynamic enzyme complex that orchestrates the final steps and transport of this alkaloid, offering new insights for synthetic biology and plant defense mechanisms. plantbiology
Australia: Ingestible Smart Sensor Boosts Non-Invasive Diagnostics
A world‑first ingestible gas‑sensing capsule, developed from RMIT University research, has been commercialised in Victoria, offering clinicians a radiation‑free, real‑time view of the gastrointestinal tract. The device moves beyond invasive procedures, targeting the roughly 40% of people who suffer from...
Reprogrammed Tregs Turn Pancreatic Tumors Immunotherapy‑Friendly
Reprogramming regulatory T cells within pancreatic tumors may transform them from immune suppressors into supporters of anti-tumor activity, offering a potential strategy to enhance immunotherapy effectiveness in this challenging cancer. immunotherapy
Reprogramming Regulatory T Cells Could Help Immunotherapy Work in Pancreatic Cancer
Researchers at Oregon Health & Science University discovered that pancreatic tumors suppress immunotherapy by recruiting large numbers of regulatory T cells (Tregs). In mouse models, an agonistic CD40 therapy not only activated tumor‑killing immune cells but also reprogrammed Tregs into...
Trinity Launches InsightsEDGE™ | Digital Twins — Generative AI Unlocks Always-On Intelligence for Life Sciences Commercial Teams
Trinity has launched InsightsEDGE™ | Digital Twins, an AI‑driven solution that builds interactive virtual replicas of healthcare professionals, patients and payers using real‑world data. The tool extends the company’s existing InsightsEDGE platform, turning one‑off research into a continuously refreshed, always‑on...
Explore Rapamycin's Role in Aging at UArizona
If you’re in Tucson next week, I’ll be giving a talk at the University of Arizona College of Pharmacy (@UAZPharmacy) on the science behind rapamycin and aging. We’ll cover what we know, what we don’t, and where the field is...
REPL RP1 Melanoma Trial Flawed; New CRL
I've never covered the REPL RP1 data in melanoma, mainly due to dislike of the trial design w/ its lack of a monotherapy arm. Sometimes you can see where things are likely headed and kicking a dog when it's down...
Fibrosis Company Avalyn Seeks NASDAQ Listing Amid Volatility: Finance Report
Avalyn Pharma, a Boston biotech focused on inhaled treatments for pulmonary fibrosis, filed a prospectus to list on NASDAQ despite ongoing market volatility. The company’s pipeline includes two Phase II programs: AP01, an inhaled pirfenidone in the Phase IIb MIST trial, and...
Scientists Successfully Made Advanced, Lab-Grown Brains—Could They Become Conscious?
Scientists have advanced brain organoid technology by connecting miniature brain tissue to prototype spinal cords, creating a four‑part assembloid that mimics the human pain‑sensory pathway. Despite this complexity, the structures contain just 0.002% of the neurons found in a full...
Finerenone Reduces Clinical Events in Patients With Heart Failure Regardless of CHD History
A prespecified analysis of the FINEARTS‑HF trial evaluated finerenone in 6,001 patients with heart‑failure with mildly reduced or preserved ejection fraction, 54% of whom had a history of coronary heart disease. Finerenone reduced the composite of cardiovascular death and heart‑failure...
Devyser Partners with Illumina
Devyser announced a strategic partnership with Illumina that will pair selected Illumina sequencing platforms with Devyser’s proprietary reagent kits. Under the agreement, Devyser’s customers can obtain the sequencers through a reagent‑commitment model rather than a traditional capital purchase. The collaboration...
Predictors of Rapid, Complete Skin Clearance With Psoriasis Biologics
A real‑world analysis of 299 moderate‑to‑severe psoriasis patients treated with biologics found that 76.3% achieved an early super‑response (PASI 100 by week 4 and maintained PASI < 1 through week 48). The strongest positive predictors were biologic‑naïve status and higher baseline neutrophil counts, while palmoplantar...
Apotex and Orbicular Secure First FDA Tentative Approval for Generic Ozempic
Apotex Corp., in partnership with Orbicular Pharmaceutical Technologies, has earned the first U.S. FDA tentative approval for its generic semaglutide injection, a biosimilar to Novo Nordisk's Ozempic. The milestone opens the door to a lower‑cost alternative for a blockbuster diabetes...
Girl Mice Grew Balls After a One-Letter DNA Change
Researchers at Bar‑Ilan University introduced a single‑letter mutation into a non‑coding DNA segment of female mice, causing them to develop testes. The alteration targeted a regulatory region previously considered "junk DNA," demonstrating that tiny changes can flip sexual development pathways....
The Insight Partners Forecasts 12.4% CAGR for Nanotech Drug Delivery Market to 2031
The Insight Partners released a market outlook projecting a 12.4% compound annual growth rate for nanotechnology-enabled drug delivery platforms from 2025 to 2031. The report cites rising chronic disease prevalence, personalized medicine, and R&D spending as key catalysts, while noting...
Daito Pharmaceutical Posts 86% Nine‑Month Profit Surge on New Drug Sales
Daito Pharmaceutical Co Ltd announced an 86% increase in nine‑month net profit to ¥2.267 billion, propelled by sales of recently launched drugs. Revenue edged up 0.3% to ¥36.732 billion, and the company issued full‑year EPS guidance of ¥84.38 per share.
Imeglimin. A New and Novel Drug Thats Better than Metformin
Imeglimin, a novel oral antidiabetic approved in Japan and the EU, improves mitochondrial bioenergetics and reduces HbA1c more effectively than metformin. Its renal excretion bypasses the CYP3A4 pathway, eliminating pharmacokinetic conflicts with rapamycin, an mTOR inhibitor used in longevity protocols....
First Detailed Insight Into Bornavirus Nucleoprotein–RNA Complex Reveals Unique Assembly
Researchers from Kyoto, Osaka Dental, and Osaka Metropolitan Universities used cryo‑electron microscopy to obtain the first high‑resolution structure of the Borna disease virus 1 (BoDV‑1) nucleoprotein‑RNA complex. The study revealed ring‑like assemblies where each nucleoprotein subunit binds eight RNA nucleotides,...
Lung Cancer Molecular Testing Nears 70%, Still Falls Short of Universal Use: Christopher D'Avella, MD
Molecular profiling for newly diagnosed advanced non‑small cell lung cancer has risen from about 50% to roughly 70% before first‑line therapy, driven by stronger guideline awareness and more targetable mutations. However, testing gaps persist, especially when biopsies are performed without...
PreCheck Pilot Program Structure
The FDA’s PreCheck Pilot Program introduces a two‑phase pathway to speed the launch of new U.S. pharmaceutical manufacturing sites. Phase 1 delivers early, structured Pre‑Operational Reviews (POR) and builds a Type V Drug Master File that captures facility design, equipment qualification, and...
Oricell Therapeutics Secures $110 Million to Take on One of Oncology's Most Vexing Problems
Oricell Therapeutics closed a pre‑IPO financing round exceeding $110 million, led by Vivo Capital and a slate of international investors. The capital will fund global clinical expansion and further development of its proprietary CAR‑T platform targeting solid tumors. Oricell’s lead candidate,...
University of Cincinnati Launches Clinical Trial to Test New Drug for Prosthetic Joint Infections
The University of Cincinnati has begun enrolling patients in Peptilogics' RETAIN trial, a randomized, double‑blind study evaluating a novel peptide solution designed to penetrate biofilm in prosthetic joint infections (PJI). The trial will compare the peptide irrigant against a saline...
Cryo-EM Structural Biology Facility Opened in San Diego by FairJourney Bio
FairJourney Bio has launched an advanced cryo‑electron microscopy (cryo‑EM) structural biology facility in San Diego, featuring two 300 kV ThermoFisher Titan Krios 5 systems. The lab brings atomic‑resolution imaging directly into the company’s antibody discovery platform, supporting everything from epitope mapping to...
Plan for Remade ACIP Panel Adds Focus on Vaccine Safety, Matching Kennedy’s Push
A federal judge recently halted most Trump-era appointments to the CDC’s Advisory Committee on Immunization Practices (ACIP), prompting the agency to draft a new charter that reshapes the panel’s composition and priorities. The revised charter emphasizes vaccine safety, mandating transparent...
5 Vaccines Under Development That Would Change the World As We Know It
Recent advances in vaccine technology are targeting five of the world’s most persistent health threats: HIV, tuberculosis, cancer, influenza, and coronaviruses. Early-phase trials show mRNA‑based germline‑targeting approaches can induce broadly neutralizing antibodies against HIV, while the M72/AS01E candidate achieved roughly...
FDA Clears Investigational New Drug Application to Test sCAR-T Therapy for Autoimmune Conditions
The FDA has cleared Calibr‑Skaggs Institute’s investigational new drug application to test its switchable CAR‑T therapy, CLBR001 + SWI019, in a phase 1 trial for autoimmune diseases. The study will enroll patients with myositis, systemic sclerosis, lupus and rheumatoid arthritis, aiming to demonstrate...
Bioanalytical Method Validation for Biomarkers
The U.S. Food and Drug Administration issued final Level 2 guidance (Docket FDA‑2017‑D‑6821) on bioanalytical method validation for biomarkers. It outlines the evidentiary standards for measuring biomarker concentrations in clinical trials and non‑clinical studies. The guidance applies to IND, NDA, BLA, ANDA,...
Alpheus Medical Advances to Phase 2b Testing of Experimental Brain Cancer Therapy
Alpheus Medical has enrolled 10 patients in a Phase 2b randomized trial of its Porphyrin Metabolite Activation (PoMA) therapy for newly diagnosed glioblastoma. PoMA uses a tumor‑selective drug activated by low‑intensity diffuse ultrasound to treat the entire affected brain hemisphere,...
Influenza Vaccination Reduces Cardiovascular Risk Following Infection
A new Danish register‑based self‑controlled case series spanning 2014‑2025 shows that influenza infection triggers a sharp, short‑lived surge in acute myocardial infarction and stroke, especially within the first three days. Prior influenza vaccination cuts the excess cardiovascular risk dramatically, with...
Ezetimibe Shows Unexpected Potential to Prevent Alzheimer’s
Ezetimibe might help prevent Alzheimer's disease... but not in the way that you think. These data really caught me off guard. But the data are the data. (long-form video linked below)
Replimune’s Advanced Melanoma Drug Rebuffed by FDA for Second Time
Replimune’s oncolytic immunotherapy RP1, aimed at unresectable advanced cutaneous melanoma, was rejected by the FDA for a second time on April 6, 2026. The agency’s complete response letter said the data, derived from a single‑arm trial, were insufficient to demonstrate substantial effectiveness,...
This Startup Is Using Blood Samples to Transform Depression Treatment
NeuroKaire, a startup founded by neuroscientists Dr. Talia Cohen Solal and Dr. Daphna Laifenfeld, has launched BrightKaire, a precision‑psychiatry test that uses a simple blood draw to predict individual responses to antidepressants. The test creates patient‑specific neurons in a dish, exposes...
Why Kidney Disease Innovation Is a Tale of Two Cities — and What It Would Take to Change That with...
John Butler, CEO of Akebia Therapeutics, explained the stark contrast between rapid innovation in rare kidney diseases and the near‑absence of new dialysis therapies, blaming regulatory uncertainty and a Medicare bundle that discourages drug development. FDA clarity on endpoints sparked...
BMS and Oxford BioTherapeutics Join Forces in TCE Discovery Pact
Bristol Myers Squibb has entered a discovery partnership with Oxford BioTherapeutics to develop T‑cell engager (TCE) therapies for solid tumours. BMS will pay an undisclosed upfront fee to access OBT’s OGAP‑Verify platform, while OBT will design and deliver pre‑clinical candidates....
Simulations Plus Posts 8% Q2 Revenue Rise, Raises FY2026 Outlook Amid AI Partnerships
Simulations Plus (SLP) posted Q2 2026 revenue of $24.3 million, up 8% year‑over‑year, and lifted its full‑year revenue guidance to $79‑$82 million. The biotech‑software firm highlighted strategic AI collaborations with three large pharmaceutical companies, while trimming its FY2026 EPS outlook due to...
Chinese Startup Unveils 20 Glowing Plant Species for Electricity‑Free City Lighting
Magic Pen Bio, a Hefei‑based nanotech startup, announced the creation of 20 engineered plant species that emit light without electricity. Founder Li Renhan says the plants need only water and fertilizer, positioning them as a low‑cost alternative for urban illumination...
Trinity Capital Secures $395 Million New Commitments, Deploys $306 Million in Q1 Biotech Investments
Trinity Capital reported $395 million of new commitments and $306 million of funded investments in the first quarter, with the bulk directed to secured loans for emerging biotech firms. The inflow and deployment signal robust capital appetite for early‑stage drug development amid...
Bacteria From Bumblebees Can Produce Vitamin B₂ in Soya Drinks
Researchers at Denmark's Technical University (DTU) used a droplet microfluidics platform to screen the bumblebee gut microbiome, identifying a Lactococcus lactis strain that ferments soy drinks while producing vitamin B₂. The transparent soy medium and fluorescence‑based detection cut screening time from...
MGNX Restarts LINNET Gene‑Therapy Trial as GSK Wins China Nod and NBIX Acquires SLNO
MacroGenics announced the FDA lifted a partial hold on its Phase 2 LINNET gene‑therapy trial, while GSK secured Chinese regulatory clearance for a new product, the FDA approved Waters' submission, and Neurocrine Biosciences completed its acquisition of SLNO. The cluster of...
OCE's Objections Caused Rejection, Not Vinay Prasad
$REPL my read of the RP1 CRL suggests OCE (CDER) took the lead in the review. Their objections led to the first rejection, as I previously reported, and nothing Replimune submitted for the second review was enough to support...
Biotech IPOs Open as Hemab Goes Public
Biotech IPO gates are opening. Congrats also to @JMaraganore (Chair) and Benny Sorensen (CEO) of Hemab, and best of luck.
FDA Delays Approval of Two Natural Food Dyes Over Safety Objections
The U.S. Food and Drug Administration announced a delay in approving two natural food colorants—beetroot red and spirulina extract—citing objections from consumer groups and safety experts. Critics say the agency skipped key carcinogenic and heavy‑metal assessments, putting manufacturers and shoppers...
FDA Approves First Gene Therapy for LAD‑I Children
FDA approves first gene therapy, Kresladi, offering a breakthrough treatment for children with the rare immune disorder LAD-I https://t.co/ezWPPEgtd0
Live CEO Interviews From Raymond James Biotech Symposium
Programming note: On Tuesday of next week I'll be broadcasting @BiotechTV interviews from the Raymond James Biotech Symposium in New York. Current confirmed CEO interviews: $SEPN $AKBA $WVE $VERA $DYN $KRRO (and maybe more). Let me know any questions for...
Estrogen Patch Shortage Hits U.S. Women as Demand Surges 26% After FDA Warning Removal
A sudden shortage of estradiol patches, triggered by the FDA’s removal of a black‑box warning, has left U.S. women scrambling for hormone replacement therapy. Demand rose 26% and experts warn the gap could persist for up to three years, underscoring...
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
Agentic AI is revolutionizing drug discovery, allowing scientists to generate candidates from simple text prompts and run extended‑reality guided experiments. In parallel, Gilead announced a deal to acquire Tubulis for up to $5 billion, strengthening its antibody‑drug conjugate portfolio. Eli Lilly and...
Other News to Note for April 10, 2026
BioWorld’s April 10 briefing highlights three notable developments. Jiangsu and Shanghai Hengrui have patented novel Nav1.8 sodium‑channel blockers, a class of compounds with potential for pain and inflammatory disease therapies. New hematopoietic stem‑cell research links chronic inflammation to early‑stage leukemia, deepening...
Zeto New Wave EEG System Wins FDA Clearance For At-Home Brain Monitoring
Zeto announced FDA 510(k) clearance for its New Wave EEG system, the company’s third FDA‑approved neuro‑diagnostic platform. The device is a 21‑electrode, gel‑free headset designed for short‑term, up‑to‑2.5‑hour recordings in outpatient clinics and patients’ homes. Integrated with Zeto’s cloud and...
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
A study from Daegu Gyeongbuk Institute of Science and Technology shows that overexpressing the neuropeptide somatostatin (SST) in mice reduces microglial activation, lowers amyloid‑β plaque density, and improves spatial memory in the 5xFAD Alzheimer’s model. In vitro, SST boosted microglial...